Lacroix-Desmazes S - Search Results

1

In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.

Pashov AD, Calvez T, Gilardin L, Maillère B, Repessé Y, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S. Pashov AD, et al. Haemophilia. 2014 Mar;20(2):176-84. doi: 10.1111/hae.12276. Epub 2013 Oct 14. Haemophilia. 2014. PMID: 24118514

2

The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A.

Lacroix-Desmazes S, Bayry J, Misra N, Kaveri SV, Kazatchkine MD. Lacroix-Desmazes S, et al. Haemophilia. 2002 Mar;8 Suppl 2:55-9. doi: 10.1046/j.1351-8216.2001.00116.x. Haemophilia. 2002. PMID: 11966855 Review.

3

Pathophysiology of inhibitors to factor VIII in patients with haemophilia A.

Lacroix-Desmazes S, Misra N, Bayry J, Artaud C, Drayton B, Kaveri SV, Kazatchkine MD. Lacroix-Desmazes S, et al. Haemophilia. 2002 May;8(3):273-9. doi: 10.1046/j.1365-2516.2002.00624.x. Haemophilia. 2002. PMID: 12010423 Review.

4

Inhibitors in haemophilia: pathophysiology.

Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Saint-Remy JM, et al. Haemophilia. 2004 Oct;10 Suppl 4:146-51. doi: 10.1111/j.1365-2516.2004.01009.x. Haemophilia. 2004. PMID: 15479388 Review.

5

Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.

Kaveri SV, Dasgupta S, Andre S, Navarrete AM, Repessé Y, Wootla B, Lacroix-Desmazes S. Kaveri SV, et al. Haemophilia. 2007 Dec;13 Suppl 5:61-4. doi: 10.1111/j.1365-2516.2007.01575.x. Haemophilia. 2007. PMID: 18078399 Review.

6

Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.

Delignat S, Repessé Y, Navarrete AM, Meslier Y, Gupta N, Christophe OD, Kaveri SV, Lacroix-Desmazes S. Delignat S, et al. Haemophilia. 2012 Mar;18(2):248-54. doi: 10.1111/j.1365-2516.2011.02679.x. Epub 2011 Nov 2. Haemophilia. 2012. PMID: 22044692

7

Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro.

Teyssandier M, André S, Gupta N, Dasgupta S, Bayry J, Kaveri SV, Lacroix-Desmazes S; ABIRISK consortium. Teyssandier M, et al. Haemophilia. 2013 May;19(3):399-402. doi: 10.1111/hae.12081. Epub 2012 Dec 18. Haemophilia. 2013. PMID: 23252683

8

Predictive immunogenicity of Refacto AF.

Delignat S, Repessé Y, Gilardin L, Dimitrov JD, Lone YC, Kaveri SV, Lacroix-Desmazes S. Delignat S, et al. Haemophilia. 2014 Jul;20(4):486-92. doi: 10.1111/hae.12348. Epub 2013 Dec 30. Haemophilia. 2014. PMID: 24372710

9

Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice.

Peyron I, Dimitrov JD, Delignat S, Gangadharan B, Planchais C, Kaveri SV, Lacroix-Desmazes S. Peyron I, et al. Haemophilia. 2015 Jan;21(1):e94-8. doi: 10.1111/hae.12579. Epub 2014 Dec 4. Haemophilia. 2015. PMID: 25471131 No abstract available.

10

Catalytic activity of antibodies against factor VIII in patients with hemophilia A.

Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Lacroix-Desmazes S, et al. Nat Med. 1999 Sep;5(9):1044-7. doi: 10.1038/12483. Nat Med. 1999. PMID: 10470082

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

237 results

Search Page